Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency: Stem Cell Selection and Manipulation

Hematology/Oncology Clinics of North America

Volumn 25, Issue 1, 2011, Pages 45-62

  Hagin, David ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Immunodeficiency; Stem cell transplantation; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD45RA ANTIGEN; CYCLOSPORIN A; LECTIN; LEUKOCYTE ANTIGEN; OKT 3; SOYBEAN AGGLUTININ;

BONE MARROW TRANSPLANTATION; CD34 SELECTION; CHRONIC DISEASE; COMBINED IMMUNODEFICIENCY; ENGRAFTMENT; FRACTIONATION; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT INFECTION; REVIEW; SHEEP ERYTHROCYTE; SURVIVAL; T CELL DEPLETION;

EID: 78651068891     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.11.004     Document Type: Review

References (75)

1. Geha R.S., Notarangelo L.D., Casanova J.L., et al. The International Union of Immunological Societies (IUIS) primary immunodeficiency diseases (PID) classification committee. J Allergy Clin Immunol 2007, 120(4):776.
2. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
3. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 2001, 357(9271):1863-1869.
4. Gatti R., Meuwissen H., Allen H., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2(7583):1366.
5. Bortin M., Rimm A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 1977, 238(7):591-600.
6. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981, 2(8242):327-331.
7. Griffith L.M., Cowan M.J., Kohn D.B., et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008, 122(6):1087-1096.
8. Zuckerman T., Rowe J.M. Alternative donor transplantation in acute myeloid leukemia: which source and when?. Curr Opin Hematol 2007, 14:152-161.
9. Tiercy J.M., Bujan-Lose M., Chapuis B., et al. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB 1/B 3/B 5/DQB 1-matched donor?. Bone Marrow Transplant (Basingstoke) 2000, 26(4):437-441.
10. Uphoff D. Preclusion of secondary phase of irradiation syndrome by inoculation of fetal hematopoietic tissue following lethal total-body x-irradiation. J Natl Cancer Inst 1958, 20:625.
11. Yunis E., Good R., Smith J., et al. Protection of lethally irradiated mice by spleen cells from neonatally thymectomized mice. Proc Natl Acad Sci U S A 1974, 71(6):2544.
12. Bortin M., Saltzstein E. Graft-versus-host inhibition: fetal liver and thymus cells to minimize secondary disease. Transplantation 1969, 8(5):712.
13. Korngold B., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978, 148(6):1687-1698.
14. Reisner Y., Linker-Israeli M., Sharon N. Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cell Immunol 1976, 25(1):129-134.
15. Reisner Y., Ravid A., Sharon N. Use of soybean agglutinin for the separation of mouse B and T lymphocytes. Biochem Biophys Res Commun 1976, 72(4):1585-1591.
16. Reisner Y., Itzicovitch L., Meshorer A., et al. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A 1978, 75(6):2933-2936.
17. Reisner Y., Ikehara S., Hodes M.Z., et al. Allogeneic hemopoietic stem cell transplantation using mouse spleen cells fractionated by lectins: in vitro study of cell fractions. Proc Natl Acad Sci U S A 1980, 77(2):1164-1168.
18. Reisner Y., Kapoor N., O'Reilly R., et al. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980, 2(8208-8209):1320-1324.
19. Reisner Y., Kapoor N., Good R., et al. Allogeneic bone marrow transplantation in mouse, monkey and man using lectin-separated grafts. Tolerance in bone marrow and organ transplantation 1984, 293. Elsevier Science Publishing Co, Amsterdam (NY). S. Slavin (Ed.).
20. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983, 61(2):341.
21. O'Reilly R., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency using histoincompatible parental marrow fractionated by soybean agglutinin and sheep red blood cells: experience in six consecutive cases. Transplant Proc 1983, 15(1):1431.
22. Friedrich W., Goldmann S.F., Vetter U., et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet 1984, 1(8380):761-764.
23. Fischer A., Durandy A., De Villartay J., et al. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood 1986, 67(2):444.
24. Filipovich A.H., McGlave P.B., Ramsay N.K., et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982, 1(8284):1266-1269.
25. Hayward A.R., Murphy S., Githens J., et al. Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency. J Pediatr 1982, 100(4):665-668.
26. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983, 62(4):873.
27. Frame J.N., Collins N.H., Cartagena T., et al. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. Transplantation 1989, 47(6):984-988.
28. Waldmann H., Hale G., Cividalli G., et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody(CAMPATH-1). Lancet 1984, 2(8401):483-485.
29. Apperley J., Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986, 1(1):53.
30. Hale G., Cobbold S., Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 1988, 45(4):753.
31. Hale G., Zhang M.J., Bunjes D., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998, 92(12):4581.
32. Waldmann H., Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005, 360(1461):1707.
33. Civin C.I., Strauss L.C., Fackler M.J., et al. Positive stem cell selection-basic science. Prog Clin Biol Res 1990, 333:387-401. [discussion: 402].
34. Sutherland D.R., Stewart A.K., Keating A. CD34 antigen: molecular features and potential clinical applications. Stem Cells 1993, 11(Suppl 3):50-57.
35. Shpall E.J., Gee A., Cagnoni P.J., et al. Stem cell isolation. Curr Opin Hematol 1995, 2(6):452-459.
36. Slatter M.A., Brigham K., Dickinson A.M., et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol 2008, 121:361-367.
37. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998, 91(10):3646.
38. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999, 340(7):508-516.
39. Small T.N., Friedrich W., O'Reilly R.J. Hematopoietic cell transplantation for immunodeficiency diseases. Thomas' hematopoietic cell transplantation 2009, 1105-1124. Blackwell Publishing Ltd. 4th edition. F.R. Appelbaun, S.J. Forman, S. Negrin (Eds.).
40. Antoine C., Müller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003, 361(9357):553-560.
41. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006, 295(5):508-518.
42. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002, 99(3):872.
43. Bertrand Y., Landais P., Friedrich W., et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J Pediatr 1999, 134(6):740.
44. Booth C., Hershfield M., Notarangelo L., et al. Management options for adenosine deaminase deficiency. Proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 2007, 123(2):139-147.
45. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111(1):439.
46. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001, 97(6):1598.
47. Cowan M.J., Neven B., Cavazanna-Calvo M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. Biol Blood Marrow Transplant 2008, 14(1S):73-80.
48. Cavazzana-Calvo M., André-Schmutz I., Dal Cortivo L., et al. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol 2009, 21:544-548.
49. Scaradavou A., Carrier C., Mollen N., et al. Detection of maternal DNA in placental/umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene. Blood 1996, 88(4):1494.
50. Neven B., Leroy S., Decaluwe H., et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009, 113(17):4114.
51. Douek D.C., McFarland R.D., Keiser P.H., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396(6712):690-695.
52. Mackall C., Granger L., Sheard M., et al. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993, 82(8):2585.
53. Dumont-Girard F., Roux E., van Lier R.A., et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998, 92(11):4464.
54. Roux E., Helg C., Dumont-Girard F., et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996, 87(9):3984.
55. Small T., Papadopoulos E., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999, 93(2):467.
56. Weinberg K., Blazar B.R., Wagner J.E., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001, 97(5):1458.
57. Patel D.D., Gooding M.E., Parrott R.E., et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 2000, 342(18):1325-1332.
58. Muller S.M., Kohn T., Schulz A.S., et al. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 2000, 96(13):4344.
59. Lewin S.R., Heller G., Zhang L., et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002, 100(6):2235.
60. Dulude G., Roy D.C., Perreault C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 1999, 189(8):1329-1342.
61. Hazenberg M.D., Otto S.A., de Pauw E.S., et al. T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood 2002, 99(9):3449.
62. Sarzotti M., Patel D.D., Li X., et al. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation 1. J Immunol 2003, 170(5):2711-2718.
63. Borghans J.A., Bredius R.G., Hazenberg M.D., et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood 2006, 108(2):763.
64. Cavazzana-Calvo M., Carlier F., Le Deist F., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007, 109(10):4575.
65. Frey J., Ernst B., Surh C., et al. Thymus-grafted SCID mice show transient thymopoiesis and limited depletion of V beta 11 T cells. J Exp Med 1992, 175(4):1067-1071.
66. Haddad E., Deist F.L., Aucouturier P., et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. Blood 1999, 94(8):2923.
67. Slatter M., Bhattacharya A., Flood T., et al. Polysaccharide antibody responses are impaired post bone marrow transplantation for severe combined immunodeficiency, but not other primary immunodeficiencies. Bone Marrow Transplant 2003, 32(2):225-229.
68. Booth C., Ribeil J.A., Audat F., et al. CD34 stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies. Br J Haematol 2006, 135(4):533-537.
69. André-Schmutz I., Six E., Bonhomme D., et al. Shortening the immunodeficient period after hematopoietic stem cell transplantation. Immunol Res 2009, 44(1):54-60.
70. Dvorak C.C., Hung G.Y., Horn B., et al. Megadose CD34 cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant 2008, 14(10):1125-1133.
71. Rachamim N., Gan J., Segall H., et al. Tolerance induction by " megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998, 65(10):1386-1393.
72. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097.
73. Bachar-Lustig E., Reich-Zeliger S., Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 2003, 102(6):1943.
74. Edelshtein Y., Ophir E., Bachar-Lustig E., et al. Ex-vivo acquisition of central memory phenotype is critical for tolerance induction by donor anti-3rd party CD8 T cells in allogeneic bone marrow transplantation. Blood (ASH Annual Meeting Abstracts) 2008, 112:2323.
75. Yu P., Xiong S., He Q., et al. Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts. Immunology 2009, 127(4):500-511.